Analgesic Effect of Resistance Training for Breast Cancer Survivors ((ANTRAC))

January 11, 2022 updated by: Gorm Henrik Fogh Rasmussen, Aalborg University

Effect of Resistance Training of Persistent Pain After Breast Cancer

Persistent pain after treatment for breast cancer is a major clinical problem, affecting 25-60 % of the patients and is a source of considerable physical disability and psychological distress. Thus, the development of novel interventions to improve pain management for these patients is of clinical importance. Resistance training (RT) is a promising tool to combat a variety of undesirable adverse effects due to breast cancer treatment. Further, research suggests that it may also be able to provide pain-relieving benefits.

Hypothesis: Resistance training will improve pain perception and physical function in the short- and long term compared to a non-training control group.

Study Overview

Detailed Description

Breast cancer is the most common cancer in women worldwide with more than a million new cases diagnosed every year [1]. Fortunately, due to better treatment options, the population of long-term survivors is increasing. This poses new demands for knowledge on how to manage late effects to the treatment regimen. Persistent pain after treatment for breast cancer is a common and underestimated problem as well as it can be a source of considerable physical disability and psychological distress [2]. Hence, the development of novel interventions to improve pain management is of high clinical relevance. Resistance training (RT) is a promising clinical therapeutic tool to improve a variety of adverse effects to breast cancer treatment [3] and may provide several pain-relieving benefits [4]. However, the efficacy of this modality for managing persistent pain after breast cancer treatment is currently unclear. Therefore, the purpose of this project is to investigate if individualized RT can modulate persistent pain after breast cancer treatment, thereby improving our understanding of how this modality may benefit patients and contribute to clinical guidelines for pain management in this clinical population.

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Northern Jutland
      • Aalborg, Northern Jutland, Denmark, 9220
        • Department of Health Science and Technology, Aalborg University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • primary diagnosis of breast cancer (grades I-IIIA).
  • adult women at least 18 years of age.
  • having received breast cancer treatment (i.e. surgery and possible adjuvant chemo and/or radiotherapy) at least 18 months before the start of the study.
  • self reported pain in the areas of the breast, shoulder, axilla, arm and/or side of body with an intensity of ≥ 3 on a numeric rating scale (0 = no pain, 10 = worst pain imaginable).
  • no signs of cancer recurrence.
  • reading, writing and speaking Danish.

Exclusion Criteria:

  • breast surgery for cosmetic reasons or prophylactic mastectomy.
  • bilateral breast cancer.
  • lymphedema.
  • other chronic pain conditions (e.g., rheumatoid arthritis).
  • previous diagnosis of fibromyalgia syndrome.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Training
Participants with persistent pain after breast cancer treatment will receive 24 sessions of individualized progressive total body resistance training, supervised by a certified strength and conditioning specialist.
The experimental group will perform a supervised progressive resistance training program, with five exercises for the upper- and lower body (box squat, bench press, trap bar deadlift, bench pull and lat pulldown), 2x/week for a 12 week period. The program will utilize a flexible progression system through three distinct training phases; 1) 2-4 sets of 10-12 repetitions, 2) 2-4 sets of 6-8 repetitions, 3) 2-4 sets of 2-4 repetitions. Number of sets are adjusted within session according to daily readiness while load is adjusted within and between sessions according to number of reps performed. A 3-5min rest period is provided throughout the program.
Other: Control
Participants with persistent pain after breast cancer treatment will be instructed to continue their everyday lifestyle and be encouraged not to engage in new forms of exercise or physical activity throughout the study period.
The control group will be instructed to continue their everyday lifestyle with no specific instruction regarding exercise and/or diet. However, they will be encouraged not to engage in new forms of exercise or physical activity throughout the study period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in pain sensitivity, assessed through pressure pain thresholds.
Time Frame: Baseline and at 3, and 6 months
Between group comparisons of treatment effect (change in pressure pain thresholds) from baseline to follow-up) will be performed. Pressure pain thresholds will be collected with a pressure algometer with a progressive increment in pressure of 30kPa.
Baseline and at 3, and 6 months
Change in pain intensity, assessed through a 11 point numeric rating scale (0 = no pain, 10 = worst pain imaginable).
Time Frame: Baseline and at 3, and 6 months
Pain intensity is collected in two different contexts; 1) recollection for the past 3 months and 2) movement evoked pain during testing and training.
Baseline and at 3, and 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Muscular strength assesses through a 1 repetition maximum (1RM)
Time Frame: Baseline and at 3, and 6 months
1RM box squat, bench press, trapbar deadlift, bench pull and lat pulldown conducted in accordance with the recommendations of the American College of Sports Medicine (ACSM)
Baseline and at 3, and 6 months
Active shoulder range of motion assessed with a universal goniometer.
Time Frame: Baseline and at 3, and 6 months
Active range of motion for the affected shoulder is collected for shoulder flexion, horizontal shoulder flexion/extension, shoulder abduction and internal/external shoulder/rotation
Baseline and at 3, and 6 months
Body composition assessed through bioelectrical impedance measurements.
Time Frame: Baseline and at 3, and 6 months
Estimates of body fat mass, fat free mass, skeletal muscle mass and bodyfat percentage are collected from bioelectrical impedance using an InBody370 device.
Baseline and at 3, and 6 months
Arm circumference measured bilaterally at a single point 30cm above the styloid process.
Time Frame: Baseline and at 3, and 6 months
Arm circumference is collected to assess potential lymphedema development. A difference in circumference of >10% between arms is considered indicative of lymphedema.
Baseline and at 3, and 6 months
Physical activity level assessed through the international physical activity questionnaire (IPAQ).
Time Frame: Baseline and at 3, and 6 months
IPAQ estimates physical activity level as "low", "moderate" or "high" from the number of days and time per day conducting either hard, moderate or easy physical activity for the pas seven days.
Baseline and at 3, and 6 months
Health related quality of life assessed through the European Organisation for Research and Treatment of Cancer (EORCT)-C30 quality of life questionaire
Time Frame: Baseline and at 3, and 6 months
The EORCT-C30 QLQ estimates quality of life through a series of questions regarding the extent to which the respondee experience various restrictions in physical function and well-being common in cancer patients, ranging from 1 (not at all) to 4 (A lot) on a four point likert scale.
Baseline and at 3, and 6 months
Quality of life assessed through the breast cancer specific European Organisation for Research and Treatment of Cancer (EORCT)-BR23 quality of life questionaire
Time Frame: Baseline and at 3, and 6 months
The EORCT-C30 QLQ estimates quality of life through a series of questions regarding the extent to which the respondee experience various restrictions in physical function and well-being common in breast cancer patients, ranging from 1 (not at all) to 4 (A lot) on a four point likert scale.
Baseline and at 3, and 6 months
Cancer fatigue assessed through the Functional Assessment of Chronic Illness Therapy (FACIT) - fatigue scale.
Time Frame: Baseline and at 3, and 6 months
The FACIT-scale estimates fatigue through a series of questions regarding the extent to which the respondee experience various symptoms of fatigue, ranging from 0 (not at all) to 4 (A lot) on a five point likert scale.
Baseline and at 3, and 6 months
Mental health assessed through the Major Depression Index (MDI)
Time Frame: Baseline and at 3, and 6 months
The MDI estimates mental health through a series of questions regarding the extent to which the respondee experience various symptoms of depression, ranging from 0 (never) to 5 (All the time) on a five point likert scale.
Baseline and at 3, and 6 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Summative process evaluation
Time Frame: At 3 months
The summative process evaluation include the following: 1) Context of the intervention described qualitatively, 2) the dose delivered as %'age of the planed sessions effectively implemented, 3) dose received as %'age of planned sessions effectively received, 4) fidelity measured through the following items: (1) whether the training groups (i.e. same participants every session) during training sessions were consistent; (2) whether the instructors delivered all their sessions as initially scheduled; (3) whether warm-up and training were offered in accordance with the time schedules initially planned; (4) whether the time schedule were respected by participants and instructors and 5) satisfaction, rated as level of agreement with a series of statements on a five-point likert scale 1=strongly disagree, 2=disagree, 3=uncertain, 4=agree, and 5=strongly agree.
At 3 months
Training log, collecting daily readiness for exertion, performance, perceived exertion level and movement evoked pain.
Time Frame: Every session for 12 weeks.
Daily readiness for exertion is assessed at two levels (mental and physical) prior to the warm up and each exercise on a 0-11 numeric rating scale (0 = no readiness, 10 = maximum readiness. Performance i collected as setsXrepsXload per exercise per session. Perceived level of exertion is assessed through a resistance training specific Rating of Perceived Exertion (RPE) scale based on repetitions in reserve. Movement-evoked pain is assessed per set for each exercise on a 11 point numeric rating scale (0= no pain, 10 = maximum pain).
Every session for 12 weeks.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Pascal Madeleine, Dr. Scient, Aalborg University
  • Study Chair: Michael Voigt, Ph. D., Aalborg University
  • Study Chair: Mathias Kristiansen, Ph. D., Aalborg University
  • Study Chair: Manuel Arroyo-Morales, Dr. Med, Universidad de Granada

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 10, 2020

Primary Completion (Actual)

September 23, 2021

Study Completion (Actual)

September 23, 2021

Study Registration Dates

First Submitted

August 6, 2020

First Submitted That Met QC Criteria

August 8, 2020

First Posted (Actual)

August 12, 2020

Study Record Updates

Last Update Posted (Actual)

January 12, 2022

Last Update Submitted That Met QC Criteria

January 11, 2022

Last Verified

January 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on Training

Subscribe